EMA Application withdrawn: Kyndrisa — BioMarin International Limited

View source ↗

Summary

The EMA withdrew the application for Kyndrisa for Duchenne muscular dystrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Kyndrisa

Snippet

Status: Application withdrawn. Therapeutic area: Muscular Dystrophy, Duchenne. MAH: BioMarin International Limited. Decision date: 24/06/2016